News
SPRO
2.540
-0.39%
-0.010
Weekly Report: what happened at SPRO last week (0504-0508)?
Weekly Report · 1d ago
Spero Therapeutics updates financial calendar with first-quarter results release date
PUBT · 05/05 20:22
Weekly Report: what happened at SPRO last week (0427-0501)?
Weekly Report · 05/04 09:48
Weekly Report: what happened at SPRO last week (0420-0424)?
Weekly Report · 04/27 09:49
Weekly Report: what happened at SPRO last week (0413-0417)?
Weekly Report · 04/20 09:48
Spero Therapeutics announces annual shareholder meeting webcast
PUBT · 04/13 21:27
Weekly Report: what happened at SPRO last week (0406-0410)?
Weekly Report · 04/13 09:50
Weekly Report: what happened at SPRO last week (0330-0403)?
Weekly Report · 04/06 09:49
Weekly Report: what happened at SPRO last week (0323-0327)?
Weekly Report · 03/30 09:50
Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives
Simply Wall St · 03/28 00:26
Spero Therapeutics Q4 revenue nearly triples, swings to profit
Reuters · 03/26 20:22
CORRECTED-Spero Therapeutics Q4 revenue nearly triples, swings to profit
Reuters · 03/26 20:22
Spero Therapeutics Non-GAAP EPS of $0.53, revenue of $41.3M
Seeking Alpha · 03/26 20:09
Spero Therapeutics FY2025 net income swings to $8.6 million; revenue rises 39.2% to $66.8 million
Reuters · 03/26 20:07
Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY
Benzinga · 03/26 20:06
*Spero Therapeutics 4Q Net $31.5M >SPRO
Dow Jones · 03/26 20:05
*Spero Therapeutics 4Q EPS 53c >SPRO
Dow Jones · 03/26 20:05
Press Release: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Dow Jones · 03/26 20:05
U.S. Earnings Preview: After Market Close March 26
Dow Jones · 03/26 19:31
Here are the major earnings after the close Thursday
Seeking Alpha · 03/26 14:00
More
Webull provides a variety of real-time SPRO stock news. You can receive the latest news about Spero Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.